Followers | 43 |
Posts | 4265 |
Boards Moderated | 0 |
Alias Born | 07/14/2010 |
Thursday, April 08, 2021 8:11:53 AM
Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%
Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%
Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600
Balance Sheet
Total Cash Per Share (mrq) 0.65
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71
Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
Recent IMMP News
- Immutep Receives A$3.6 million R&D Tax Incentive from French Government • GlobeNewswire Inc. • 09/24/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/24/2024 10:06:57 AM
- New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma • GlobeNewswire Inc. • 09/18/2024 12:00:00 PM
- Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer • GlobeNewswire Inc. • 09/16/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/10/2024 01:54:28 AM
- Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024 • GlobeNewswire Inc. • 08/20/2024 12:00:00 PM
- Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Immutep to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/07/2024 12:00:00 PM
- Immutep Quarterly Activities Report Q4 FY24 • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 07/22/2024 12:00:00 PM
- Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression • GlobeNewswire Inc. • 07/11/2024 10:40:40 PM
- Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results • GlobeNewswire Inc. • 07/03/2024 12:00:00 PM
- Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Immutep successfully completes institutional placement and institutional component of entitlement offer • GlobeNewswire Inc. • 06/05/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 11:35:55 AM
- Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial • GlobeNewswire Inc. • 06/03/2024 12:38:39 AM
- Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 • GlobeNewswire Inc. • 05/15/2024 12:00:00 PM
- Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Immutep Quarterly Activities Report Q3 FY24 • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B • GlobeNewswire Inc. • 04/24/2024 12:00:00 PM
- Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Immutep Announces First Clinical Data from 90mg Dosing of Efti • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 09:01:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM